The 10 most recent market catalysts affecting $TXG, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 10, 2026
Corporate Catalyst
Neutral
Impact 55
10x Genomics To Incorporate Lunit's AI-Powered Pathology Platform Into Its Oncology Biomarker Discovery Workflow
This 8-K filing announces a collaboration where 10x Genomics will incorporate Lunit's AI pathology platform, Lunit SCOPE IO, into its oncology biomarker discovery workflow. This is…
Sep 1, 2026
Corporate Catalyst
Neutral
Impact 60
RBC Capital Initiates Coverage On 10x Genomics with Sector Perform Rating, Announces Price Target of $70
RBC Capital's initiation of coverage on 10x Genomics (TXG) with a 'Sector Perform' rating and a $70 price target provides a new data point for investors. This event is significant …
Aug 31, 2026
Corporate Catalyst
Bearish
Impact 65
Jury Awards 10x Genomics Millions in Patent Lawsuit Against Qiagen Unit
10x Genomics (TXG) won a significant patent infringement lawsuit against Parse Biosciences, a subsidiary of Qiagen (QGEN), resulting in a $4.8 million damages award. This is a clea…
Aug 10, 2026
Corporate Catalyst
Bullish
Impact 75
10x Genomics shares are trading higher after Canaccord raised its price target on the stock from $50 to $60.
This headline indicates a significant positive corporate catalyst for 10x Genomics. An analyst upgrade, especially with a notable price target increase, often reflects improved fun…
Aug 10, 2026
Corporate Catalyst
Bullish
Impact 55
Canaccord Genuity Maintains Buy on 10x Genomics, Raises Price Target to $60
Canaccord Genuity analyst Kyle Mikson has maintained a 'Buy' rating on 10x Genomics (TXG) and raised the price target from $50 to $60. This indicates a strengthened conviction from…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 92
Torex Gold Resources Q2 Adj. EPS $0.90 Misses $1.22 Estimate, Sales $406.900M Miss $420.000M Estimate
Torex Gold Resources (TXG) announced Q2 adjusted EPS of $0.90, missing the analyst consensus of $1.22 by 26.23%, and sales of $406.9 million, missing the $420 million estimate by 3…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 75
10x Genomics Raises FY2026 Sales Guidance from $600.000M-$625.000M to $610.000M-$630.000M vs $613.851M Est
10x Genomics (TXG) filed an 8-K to announce an upward revision to its fiscal year 2026 sales guidance. The company now expects sales to be between $610 million and $630 million, up…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 92
10x Genomics Q2 EPS $(0.14) Beats $(0.24) Estimate, Sales $151.000M Beat $146.788M Estimate
10x Genomics (TXG) announced Q2 results that showed a loss of $(0.14) per share, which was better than the $(0.24) estimate, and sales of $151.000 million, exceeding the $146.788 m…
Jul 17, 2026
Corporate Catalyst
Bullish
Impact 55
Leerink Partners Maintains Market Perform on 10x Genomics, Raises Price Target to $40
Leerink Partners analyst Mike Kratky has updated their coverage on 10x Genomics, maintaining a 'Market Perform' rating but notably raising the price target from $23 to $40. This ac…
Jul 14, 2026
Corporate Catalyst
Bullish
Impact 55
Canaccord Genuity Maintains Buy on 10x Genomics, Raises Price Target to $50
Canaccord Genuity's analyst Kyle Mikson has maintained a 'Buy' rating on 10x Genomics (TXG) and significantly raised the price target from $32 to $50. This action signals increased…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.